We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2380:HKEXNDFOS Co., Ltd. Analysis

Data as of 2026-06-07 - not real-time

NT$5.70

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The stock is trading just above its 20‑day and 50‑day simple moving averages, indicating a short‑term bullish bias, while the 14‑day RSI hovers around the 50‑point midpoint, suggesting neutral momentum. Technical indicators show a bearish MACD crossover with the histogram in negative territory and a decreasing volume trend, which together flag weakening buying pressure. The price sits near a identified support level of roughly 5.30 TWD and faces resistance near 6.44 TWD, while recent volatility has spiked above 60% on a 30‑day basis, and the computed beta is slightly negative, implying limited correlation with broader market moves.
Fundamentally, the company trades at a very low forward PE of under 8× versus an industry average above 30×, and its price‑to‑book ratio is well under 1, painting a picture of apparent cheapness. However, a discounted cash‑flow model caps fair value near 2.0 TWD, far below the current market price, and the balance sheet shows a high debt‑to‑equity ratio exceeding 180%, with free cash flow turning negative. No dividend is paid, and earnings growth is modest at around 12% YoY, leaving the valuation more aligned with a value narrative but with significant downside risk.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish MACD crossover and negative histogram
  • Decreasing volume trend with high recent volatility
  • Price proximity to the near‑term support level

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Price remains above short‑term moving averages
  • Low PE relative to industry but DCF indicates overvaluation
  • Elevated debt level and negative free cash flow

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Significant valuation discount on PE and PB metrics
  • Potential for earnings improvement given modest revenue growth
  • Geographic diversification offering upside if geopolitical tensions ease

Key Metrics & Analysis

Financial Health

Revenue Growth12.20%
Profit Margin2.12%
P/E Ratio7.9
ROE12.63%
ROA3.06%
Debt/Equity181.10
P/B Ratio0.6
Op. Cash FlowNT$48.0M
Free Cash FlowNT$-52235500
Industry P/E32.6

Technical Analysis

TrendBullish
RSI49.9
SupportNT$5.30
ResistanceNT$6.44
MA 20NT$5.80
MA 50NT$5.61
MA 200NT$5.46
MACDBearish
VolumeDecreasing
Fear & Greed Index83.02

Valuation

Fair ValueNT$2.03
GradeOvervalued
TypeValue

Risk Assessment

Beta-0.23
Volatility62.64%
Sector RiskMedium
Reg. RiskLow
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.